Primary cutaneous anaplastic large-cell lymphoma: a review of the SEER database from 2005 to 2016.
Journal
Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
revised:
27
04
2021
received:
13
12
2020
accepted:
01
06
2021
pubmed:
4
6
2021
medline:
4
2
2022
entrez:
3
6
2021
Statut:
ppublish
Résumé
Primary cutaneous anaplastic large-cell lymphoma (PC-ALCL) is a rare T-cell lymphoma. A prior analysis of the Surveillance, Epidemiology, and End Results (SEER) database reported only 157 cases of localized primary cutaneous CD30+ T-cell lymphoproliferative disorders (PC-ALCL and lymphomatoid papulosis) from 1973 to 2004. Our analysis of the SEER database since 2004 is the largest to date and our results improve our understanding of this disease and their potential prognostic factors. We used the SEER database to retrospectively identify patients. Survival was analysed using the Kaplan-Meier method, and log-rank tests were used to compare survival distributions. There were 501 cases of PC-ALCL recorded from 2005 to 2016. Overall survival rates at 5 and 10 years were found to be 80.6% (95% CI 76.3%-84.3%) and 61.5% (95% CI 54.1%-68.1%) respectively. Age ≥ 60 years [hazard ratio (HR) = 1.09, P = 0.001 and use of chemotherapy (HR = 1.86, P = 0.01)] were associated with lower overall survival. In contrast to the 1973-2004 cohort, the head and neck site was not significantly associated with prognosis on multivariate analysis. PC-ALCL has been increasingly recognized over the past decade. Age > 60 years and use of chemotherapy are associated with a worse outcome. Contrary to prior studies, location was not associated with poor survival.
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1420-1426Informations de copyright
© 2021 British Association of Dermatologists.
Références
Korgavkar K, Xiong M, Weinstock M. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol 2013; 149: 1295-9.
Willemze R, Cerroni L, Kempf W et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019; 133: 1703-14.
Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders: a proposal for classification and guidelines for management and treatment. J Am Acad Dermatol 1993; 28: 973-80.
Bekkenk MW, Geelen FA, van Voorst Vader PC et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch cutaneous lymphoma group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95: 3653-61.
Liu HL, Hoppe RT, Kohler S et al. CD30-cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol 2003; 49: 1049-58.
Berge RL, Oudejans JJ, Ossenkoppele GJ et al. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol 2000; 53: 445-50.
National Institutes for Health. National Cancer Institute. Surveillance, Epidemiology, and End Results program. Primary cutaneous anaplastic large cell lymphoma. 2017. Available at: https://seer.cancer.gov/seertools/hemelymph/51f6cf56e3e27c3994bd5312/ (accessed 4 June 2021).
Yu J, Blitzblau R, Decker R et al. Analysis of primary CD30+ cutaneous lymphoproliferative disease and survival from the Surveillance, Epidemiology, and End Results database. J Clin Oncol 2008; 26: 1483-8.
Woo D, Jones C, Vanoli-Storz M et al. Prognostic factors in primary cutaneous anaplastic large cell lymphoma characterization of clinical subset with worse outcome. Arch Dermatol 2009; 145: 667-74.
Brooken N, Goerdt S, Klemke C-D. Clinical spectrum of primary cutaneous CD30-positive anaplastic large cell lymphoma: an analysis of the Mannheim cutaneous lymphoma registry. J Dtsch Dermatol Ges 2012; 10: 331-9.
Benner M, Willemze R. Applicability and prognostic value of the new TNM classification system in 135 patients with primary cutaneous anaplastic large cell lymphoma. Arch Dermatol 2009; 145: 1399-404.
Hallermann C, Niermann C, Fischer R-J et al. Survival data for 299 patients with primary cutaneous lymphomas: a monocentre study. Acta Derm Venereol 2011; 91: 521-5.
Hapgood G, Pickles T, Sehn L et al. Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia cancer agency experience. Br J Haematol 2017; 176: 234-40.
Maurelli M, Tessari G, Colato C et al. Incidence and ten-year follow-up of primary cutaneous lymphomas: a single-centre cohort study. Eur J Dermatol 2018; 28: 44-9.
Melchers C, Willemze R, Bekkenk M et al. Evaluation of treatment results in multifocal primary cutaneous anaplastic large cell lymphoma: report of the Dutch cutaneous lymphoma group. Br J Dermatol 2018; 179: 724-31.
Paulli M, Berti E, Rosso R et al. CD30/Ki-1-positive lymphoproliferative disorders of the skin: clinicopathologic correlation and statistical analysis of 86 cases-a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous lymphoma project group. J Clin Oncol 1995; 12: 1343-54.
Vergler B, Beylot-Barry M, Pulford K et al. Statistical evaluation of diagnostic and prognostic features of CD30 cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases. Am J Surg Pathol 1998; 22: 1192-202.
Beljaards RC, Kaudewitz P, Berti E et al. Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favourable prognosis: a European multicenter study of 47 patients. Cancer 1993; 71: 2097-104.
Bekkenk MW, Geelen FA, van Voorst Vader PC et al. Primary and secondary cutaneous CD30(-) lymphoproliferative disorders: a report from the Dutch cutaneous lymphoma group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95: 3653-61.
Sugaya M, Fujita H, Izutsu K et al. Primary cutaneous anaplastic large cell lymphoma with leg involvement: a case report and review of 11 cases. J Dermatol 2011; 38: 1009-12.
Maruta Y, Hamada T, Fukamatsu H et al. Clinical outcomes of primary cutaneous anaplastic large cell lymphoma: data from a single Japanese centre. Eur J Dermatol 2017; 27: 669-71.
Stadler R, Assaf C, Klemke C-D et al. Short German guidelines: cutaneous lymphomas. J Dtsch Dermatol Ges 2008; 6: S25-31.
Willemze R, Hodak E, Zinzani Pl et al. Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24: vi149-54.
Kempf W, Pfaltz K, Vermeer MH et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011; 118: 4024-35.
Shinohara MM, Shustov A. How I treat primary cutaneous CD30+ lymphoproliferative disorders. Blood 2019; 134: 515-24.